These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19645220)

  • 1. The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults.
    Iida S; Kinoshita H; Kawanishi T; Hayashi M
    Eur J Drug Metab Pharmacokinet; 2009; 34(2):107-15. PubMed ID: 19645220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ceftriaxone in patients undergoing continuous renal replacement therapy.
    Goto K; Sato Y; Yasuda N; Hidaka S; Suzuki Y; Tanaka R; Kaneko T; Nonoshita K; Itoh H
    J Basic Clin Physiol Pharmacol; 2016 Nov; 27(6):625-631. PubMed ID: 27497425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ceftriaxione, a third-generation cephalosporin, in pediatric patients.
    Fukumoto K; Aida S; Oishi T; Ueno K
    Biol Pharm Bull; 2009 Jul; 32(7):1139-41. PubMed ID: 19571374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indications for a ceftriaxone dosing regimen in Japanese paediatric patients using population pharmacokinetic/pharmacodynamic analysis and simulation.
    Iida S; Kawanishi T; Hayashi M
    J Pharm Pharmacol; 2011 Jan; 63(1):65-72. PubMed ID: 21155817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration.
    Ulldemolins M; Bastida C; Llauradó-Serra M; Csajka C; Rodríguez A; Badia JR; Martín-Loeches I; Soy D
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1169-1180. PubMed ID: 33559708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and bacteriological studies of ceftriaxone (CTRX) once daily administration in pediatric patients with respiratory tract infections].
    Hasui M; Kobayashi Y; Harada Y; Ono A; Okazaki H; Kino M; Hara T
    Jpn J Antibiot; 2001 Oct; 54(10):532-40. PubMed ID: 11771335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical and fundamental studies on ceftriaxone (CTRX) against urinary tract infections].
    Nishio S; Yoshihara H
    Hinyokika Kiyo; 1988 May; 34(5):937-42. PubMed ID: 3177133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram.
    Grégoire M; Dailly E; Le Turnier P; Garot D; Guimard T; Bernard L; Tattevin P; Vandamme YM; Hoff J; Lemaitre F; Verdier MC; Deslandes G; Bellouard R; Sébille V; Chiffoleau A; Boutoille D; Navas D; Asseray N
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bacteriological, pharmacokinetic and clinical evaluations of ceftriaxone in the pediatric field. Pediatric study group of ceftriaxone].
    Fujii R; Meguro H; Arimasu O; Tagaya M; Fujita K; Sakata H; Yoshioka H; Maruyama S; Sanae N; Nagamatsu I
    Jpn J Antibiot; 1986 Aug; 39(8):1988-2008. PubMed ID: 3540338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bacteriological, pharmacokinetic and clinical studies on the use of ceftriaxone in the perinatal period].
    Cho N; Fukunaga K; Kunii K; Deguchi K
    Jpn J Antibiot; 1988 Feb; 41(2):180-95. PubMed ID: 3286925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetic and clinical studies on ceftriaxone in the perinatal period].
    Yamamoto T; Yasuda J; Kanao M; Okada H
    Jpn J Antibiot; 1988 Feb; 41(2):201-9. PubMed ID: 3373740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling.
    Blumer JL; Reed MD; Kaplan EL; Drusano GL
    Pediatrics; 2005 Oct; 116(4):927-32. PubMed ID: 16199703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetic and clinical evaluations of ceftriaxone in neonates and premature infants].
    Motohiro T; Oda K; Aramaki M; Tanaka K; Kawakami A; Shimada Y; Koga T; Tomita S; Sakata Y; Fujimoto T
    Jpn J Antibiot; 1988 Mar; 41(3):276-305. PubMed ID: 3404647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the efficacy of ceftriaxone in acute suppurative otitis media and acute exacerbation of chronic suppurative otitis media. A comparative study with cefotiam as the control].
    Baba S; Mori Y; Suzuki K; Unno T; Kawabori S; Yanai T; Nonaka S; Takasaka T; Awataguchi T; Furuuchi I
    Jpn J Antibiot; 1989 Jan; 42(1):212-47. PubMed ID: 2523493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftriaxone dosing in patients admitted from the emergency department with sepsis.
    Heffernan AJ; Curran RA; Denny KJ; Sime FB; Stanford CL; McWhinney B; Ungerer J; Roberts JA; Lipman J
    Eur J Clin Pharmacol; 2021 Feb; 77(2):207-214. PubMed ID: 32974748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chorea-like symptoms and high blood concentration of ceftriaxone in a patient undergoing hemodialysis: A case report.
    Yokoyama Y; Hosokawa N; Kudo T; Goda H; Ito K; Suzuki M; Funakoshi R
    J Infect Chemother; 2020 Mar; 26(3):285-288. PubMed ID: 31680037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects.
    Sharma VD; Singla A; Chaudhary M; Taneja M
    AAPS PharmSciTech; 2016 Oct; 17(5):1192-203. PubMed ID: 26644225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental verification of factors influencing calcium salt formation based on a survey of the development of ceftriaxone-induced gallstone-related disorder.
    Ito R; Yoshida A; Taguchi K; Enoki Y; Yokoyama Y; Matsumoto K
    J Infect Chemother; 2019 Dec; 25(12):972-978. PubMed ID: 31186195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis.
    Wang YK; Wu YE; Li X; Tian LY; Khan MW; Tang BH; Shi HY; Zheng Y; Hao GX; van den Anker J; You DP; Zhao W
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical and pharmacokinetics studies of ceftriaxone upon 2g once daily administration in respiratory tract infections].
    Ishioka S; Yamakido H; Inyaku K; Hasegawa K; Yamakido M; Akagawa T; Kuwabara M; Kodomari Y; Kawamoto M; Arita H
    Jpn J Antibiot; 1991 Jun; 44(6):605-13. PubMed ID: 1890721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.